We're here to support GPs in identifying the signs of cancer and ensuring patients are referred at the right time
Research breakthroughs, new facilities and staff appointments.
Our in-house hospital magazine.
The Royal Marsden Cancer Charity raises money solely to support The Royal Marsden. With your help we can continue to be there for everyone who needs us.
It’s important to understand the difference between watchful waiting and active surveillance in order to make an informed decision about a patient’s prostate cancer treatment plan
Dr Chris Parker, Consultant Clinical Oncologist, with a patient
Because prostate cancer often grows very slowly, some men might never need treatment. Therefore approaches known as watchful waiting or active surveillance are often recommended.
This means regular, very close monitoring of the cancer so that the patient can be offered curative treatment if the cancer progresses. This is suitable for most men with low risk prostate cancer. Close monitoring is required, with PSAs, regular MRIs and sometimes repeat biopsies. Treatment (surgery, radiotherapy or brachytherapy) is offered if and when the cancer progresses.
This term is used to describe a non-intensive form of follow-up that rarely involves tests and relies more heavily on changes in a patient’s symptoms to identify if treatment is needed. This is a non-curative strategy for patients who have multiple comorbidities or a short life expectancy. Palliative treatment is only advised if the patient develops symptoms from the primary cancer or the metastases.
It’s important for GPs to know the different treatment intents of the two strategies, which are sometimes confused.
